Larry Tjoelker
Keine laufenden Positionen mehr
Profil
Larry W.
Tjoelker worked as a Science Director at Omeros Corp.
from 2011 to 2017.
He also served as a Director of Discovery Technologies at Theraclone Sciences, Inc. He held the position of Senior Director of Research at XORI Corp.
from 2009 to 2012.
Additionally, he worked as a Director of Cancer Discovery at MacroGenics, Inc. from 2002 to 2007.
Dr. Tjoelker was a Senior Scientist at ICOS Corp.
He is currently working as a Vice President of Research at Nevis Brands, Inc. from 2018 to 2022.
Dr. Tjoelker holds a doctorate degree from the University of Pennsylvania and the University of Michigan.
Ehemalige bekannte Positionen von Larry Tjoelker
| Unternehmen | Position | Ende |
|---|---|---|
| NEVIS BRANDS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2022 |
| OMEROS CORPORATION | Corporate Officer/Principal | 01.04.2017 |
XORI Corp.
 XORI Corp. BiotechnologyHealth Technology XORI Corp. provides health technology services. It develops technology for the rapid discovery and development of monoclonal antibodies (MAbs). The firm validates the technology on a variety of targets and develops superior products for cancer therapy, immune disorders, and infectious diseases. The company was founded by Nancy Maizels in 2009 and is headquartered in Seattle, WA. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2012 |
| MACROGENICS, INC. | Corporate Officer/Principal | 01.01.2007 |
Theraclone Sciences, Inc.
 Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Ausbildung von Larry Tjoelker
| University of Pennsylvania | Doctorate Degree |
| University of Michigan | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MACROGENICS, INC. | Health Technology |
| NEVIS BRANDS INC. | Health Technology |
| OMEROS CORPORATION | Health Technology |
| Private Unternehmen | 3 |
|---|---|
XORI Corp.
XORI Corp. BiotechnologyHealth Technology XORI Corp. provides health technology services. It develops technology for the rapid discovery and development of monoclonal antibodies (MAbs). The firm validates the technology on a variety of targets and develops superior products for cancer therapy, immune disorders, and infectious diseases. The company was founded by Nancy Maizels in 2009 and is headquartered in Seattle, WA. | Health Technology |
ICOS Corp.
 ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Health Technology |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Commercial Services |
